Back to results
US 2020/0376100 A1Published application
Immunotherapy of solid tumors by vaccination with transgenic leishmania expressing cancer vaccines and with recombinant vaccines with leishmania as adjuvants
AssigneeRosalind Franklin Univ. of Medicine and Science
InventorsKwang-Poo Chang, Bala K. Kolli
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of vaccination against cancer by providing a sample of a photo-inactivated Leishmania optionally transgenically modified to express a cancer antigen such as alpha-enolase; optionally providing an effective amount of an alpha-enolase; and delivering an effective amount of the sample and/or the alpha-enolase to a patient in need thereof.
Claims20
A method for vaccination against cancer comprising:
- providing a sample of a photo-inactivated Leishmania;
- providing a sample of GST-alpha-enolase;
- mixing the photo-inactivated Leishmania with the GST-alpha-enolase sample to form a vaccine mixture;
- and,
- delivering an effective amount of the vaccine mixture to a patient in need thereof.
2 more elements
A container of a solution for vaccination against cancer comprising:
- a mixture of a photo-inactivated Leishmania and a GST-alpha-enolase.
A method for treating a solid tumor in a patient comprising:
- obtaining a sample of peripheral blood mononuclear cells (PBMC) cells from the patient;
- isolating CD14 positive monocytes from the PBMC sample;
- maturing the CD14 positive monocytes into mature dendritic cells;
- co-cultivating the mature dendric cells with isolated T cells to activate CD8+ T cells and cytotoxic T lymphocytes activity;
- providing a sample of a photo-inactivated Leishmania;
- mixing the mature dendritic cells with the Leishmania sample to form a vaccination solution;
- and,
- delivering an effective amount of the vaccination solution to the patient.
5 more elements
Dependencies are inferred from the claim text.